Nuvalent Inc Total Liabilities
Nuvalent Inc total liabilities. Based on the latest financial reports, Nuvalent Inc (NUVL) has total liabilities worth $156.78 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Nuvalent Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Nuvalent Inc (2019–2025)
Total liabilities of Nuvalent Inc from 2019 to 2025. This chart illustrates how Nuvalent Inc's total liabilities have evolved over time, based on quarterly financial data.
Nuvalent Inc Competitors by Total Liabilities
The table below lists competitors of Nuvalent Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ALSTOM S.A. UNSP.ADR 1/10
F:AOMU
|
Germany | €24.22 Billion |
|
Banca Transilvania S.A.
RO:TLV
|
Romania | RON201.12 Billion |
|
Orient Sec Co Ltd
SHG:600958
|
China | CN¥431.65 Billion |
|
Ivanhoe Mines Ltd.
TO:IVN
|
Canada | CA$1.76 Billion |
|
China Spacesat Co Ltd
SHG:600118
|
China | CN¥5.25 Billion |
|
Indra A
MC:IDR
|
Spain | €4.88 Billion |
|
YTO Express Group Co Ltd
SHG:600233
|
China | CN¥17.82 Billion |
|
thyssenkrupp AG
XETRA:TKA
|
Germany | €17.74 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Nuvalent Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Nuvalent Inc total assets.
Liquidity & Leverage Metrics
Nuvalent Inc Total Liabilities Ratios Explained
Nuvalent Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nuvalent Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nuvalent Inc (2019–2025)
The table below shows the annual total liabilities of Nuvalent Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $164.37 Million | +128.41% |
| 2024-12-31 | $71.96 Million | +126.13% |
| 2023-12-31 | $31.82 Million | +63.35% |
| 2022-12-31 | $19.48 Million | +121.70% |
| 2021-12-31 | $8.79 Million | -79.06% |
| 2020-12-31 | $41.97 Million | +104.01% |
| 2019-12-31 | $20.57 Million | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more